ZNF106 and Familial prostate cancer: Of our 22 findings, two variants were suggestively associated with any 2+ primary cancers, rs555607708 (OR [95% CI] = 2.72 [1.79, 4.15], p = 3.10 × 10−6), a frameshift variant in CHEK2 known to be associated with risk at many cancer sites [29], and rs146381257 (OR [95% CI] = 7.82 [3.28, 18.62], p = 3.45 × 10−6), a 5′upstream variant in ZNF106. The risk-increasing allele for rs555607708 (CHEK2) was most commonly found among individuals with at least one breast cancer (41.9%), prostate cancer (30.6%), melanoma (22.6%), or cervical cancer (16.1%) (Fig. 2).